car-t

Addition to the Conditional Monge Gap to extend it to Chimeric Antigen Receptor T cell scRNAseq data

Systematic pipeline for identifying combinatorial CAR-T targets in acute myeloid leukemia (AML) using single-cell RNA-seq data

Files and code used to generate the CARTAR app to identify and validate CAR targets for cancer treatment.

Single-cell transcriptomic profiling of CAR T cells expressing synthetic receptors, termed "velocity CAR T" cells.

Files and code used to generate the CARTAR app to identify and validate CAR targets for cancer treatment.

Interactive dashboard tracking CAR-T, CAR-NK, CAAR-T, and CAR-γδ T clinical trials across heme- and solid-onc from ClinicalTrials.gov v2. Sister app to Rheumatology-CAR-T-Trials-Monitor.

Single-cell analysis of CAR T-cell therapy responses, identifying cellular signatures and pathways associated with treatment outcomes.

Evidence-traceable CD19 CAR-T research simulator with patent sequence verification, source-scoped lot criteria, and population and agent-based models.

Quantitative analysis of single-cell CAR-T and TIL killing kinetics from microwell co-culture imaging: EM mixture models for per-well kill rate, predator-prey ODE fits, and single-effector-cell statistics

R analysis of xCELLigence real-time impedance killing assays for T/CAR-cell and NK cytotoxicity

Personalized lymphoma therapy design with Gemma 4, AlphaFold, RFdiffusion. Kaggle Gemma 4 Good Hackathon submission.

Open dataset of multiple myeloma clinical trials registered in China, curated from NMPA/CDE filings with normalized trial centers, populations and registry status. CC BY 4.0.

MedTourChina CAR-T cell therapy vertical hub — cart.medtourchina.net

Cell Design Labs — independent third-party profile of a public API surface, by API Evangelist. Cell Design Labs, Inc. was a biotherapeutics company based at 5858 Horton Street, Emeryville, California, that engineered immune cells into "smart, living therapies" for cancer and other diseases.

Umoja Biopharma — independent third-party profile of a public API surface, by API Evangelist. Umoja Biopharma is a Seattle-based clinical-stage immuno-oncology company developing in vivo CAR T cell therapies for cancer. Its VivoVec lentiviral platform generates CAR T cells directly in a patient's body, removing the ex vivo manufacturing step of tra

AbelZeta Pharma — independent third-party profile of a public API surface, by API Evangelist. AbelZeta Pharma is a global clinical-stage cell therapy company discovering, developing, and manufacturing T-cell-based immunotherapeutics for cancer and immunological diseases. Its pipeline centers on Chimeric Antigen Receptor (CAR)-T cell technology acro

Kyverna Therapeutics — independent third-party profile of a public API surface, by API Evangelist. Kyverna Therapeutics (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company headquartered in Emeryville, California, developing engineered T cell therapies for patients suffering from autoimmune diseases.

Evidence-bounded antigen-fragment design for SNIPR receivers, at human-membrane-proteome scale. Deterministic batch screening with traceable candidates, four-class recommendations and reconciled coverage summaries.

Stylus Medicine — independent third-party profile of a public API surface, by API Evangelist. Stylus Medicine is a Cambridge, Massachusetts biotechnology company developing in vivo genetic medicines built on engineered recombinases. Its platform aims to generate precise, durable CAR-T cells directly inside the body using cell-targeted lipid nanopar

Using scRNA-seq, machine learning, and online datasets to find candidate target antigens for repurposing CAR T-cell therapy for autoimmune diseases.